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Background: To compare the accuracy of different imaging modalities, alone and in combination in predicting
findings at surgery after preoperative chemoradiation for locally advanced rectal cancer.
Methods: Following chemoradiation, tumors were reclassified on the basis of findings on pelvic computed
tomography (CT) (94 patients), endorectal ultrasonography (EUS) (138 patients) alone or by both CT and EUS
(80 patients). The ability of the imaging modalities, to predict the pathologic T status, N status, and TNM stage
at surgery was evaluated and compared.
Results: Mean age of the patients was 64.5 years (range 28–88 years); 55% were male. CT and EUS combined had a
positive predictive value of 20% for pathologic pT1 stage, 29% for pT1, 29% for pT2, and 58% for pT3. Predictive
values for the operative TNM stage were 50% for stage I, 45% for stage II, and 31% for stage III. These values did
not exceed those for each modality alone.
Conclusion: The performance of preoperative CT and EUS in predicting the T and TNM stage of rectal cancer at
surgery is poor. Neither modality alone nor the two combined is sufficiently accurate to serve as the basis for
decisions regarding treatment modification.
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Preoperative concurrent chemoradiation (CCRT) is rou-
tinely performed for locally advanced rectal cancer (LARC)
to achieve downstaging of the tumor and thereby enhance
its resectability. Additional goals are to increase the
probability of a sphincter-saving procedure, reduce the
risk of local recurrence, and possibly, improve survival
[1-5]. The response to CCRT is evaluated by preoperative
imaging studies, usually endorectal ultrasonography (EUS),
computed tomography (CT), positron emission tomog-
raphy (PET), or magnetic resonance imaging (MRI) [6-9].
Their accuracy is extremely important as the findings* Correspondence: dickmanr1@gmail.com
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reproduction in any medium, provided the orform the basis for planning the surgical approach. Each
modality is advantageous in different areas; CT may
be used to assess both local tumor extent and regional
or distant metastases; MRI may be useful in identifying
infiltration of the mesorectal fascia; and EUS is considered
more accurate for assessing tumor growth in the mucosa
and rectal wall [10].
Overall, most studies that investigated the treatment
of LARC assessed the performance of a single imaging
modality in identifying the pathologic stage at surgery
[7-9,11-13]. Only a few analyzed the predictive accuracy
of combinations of imaging modalities in the same group
of patients [10,14,15]. The aim of the present study was to
compare the performance of CT and EUS, alone and in
combination, in predicting the pathological stage following
CCRT in patients with LARC.al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Patients
The database of the Institute of Oncology, Davidoff
Center, Rabin Medical Center was searched for all
patients who received preoperative CCRT for LARC
between 1997 and 2007. Only those with histologically
confirmed LARC, defined as clinical T3-T4 Nx tumors, Tx
N + tumors, or distal (up to 6 cm from the anal verge)
T2N0 tumors and no evidence of distant metastases were
included in the study. Pretreatment evaluation in all cases
consisted of a medical history and clinical examination,
colonoscopy, blood tests (complete blood count, serum
chemistry and carcinoembryonic antigen tumor marker),
abdominal and pelvic CT, chest X-rays, and EUS. Some
patients also underwent chest CT, PET, and pelvic MRI.
Tumor resection with curative intent was offered to all
patients. The study was approved by the Human Subjects
Committee of the Rabin Medical Center.
Preoperative concurrent chemoradiation
Following clinical assessment, patients underwent the
standard external-beam radiotherapy protocol consisting
of a dose of 45 Gray (Gy) in 1.8 Gy daily fractions, 5 times
per week for 5 weeks, with a boost to the tumor of
5.4-9.0 Gy. The dose was prescribed to the isodose
encompassing the primary tumor and the internal iliac
nodes using 6 or 18Mv photons and a 3-field planning
technique. The perineum was blocked as much as possible
in the lateral fields. Concurrent chemotherapy was started
on the first day of radiotherapy and consisted of a
fluoropyrimidine-based regimen: continuous infusion
of 5-fluorouracil (5FU), bolus 5FU, oral tegafur-uracil
with leucovorin, or oral capecitabine.
Preoperative restaging by imaging
Four to six weeks after completion of CCRT, restaging
was performed using CT and EUS. As PET and MRI
were performed only occasionally, their results were
not included in the analysis. Tumors were classified as
T0 to T4 and N0 or N + according to the findings for
each staging modality; the overall preoperative stage
was defined as the highest T and N stages identified by
CT or EUS.
Response to CCRT and operative procedure
Surgery was performed 4–8 weeks after completion of
CCRT. The type of surgical procedure, namely, low
anterior resection, abdominoperineal resection, or local
excision, was left to the discretion of the surgeon. Local
excision was performed in patients with a complete
clinical response after CCRT who preferred it over
standard radical surgery. Complete clinical response
was defined as no evidence of residual disease on
digital rectal examination and rigid proctorectoscopy ora finding of a localized scar or superficial ulcer without
wall thickening or extraluminal mass on transrectal
ultrasound. Local excision was also performed in patients
with clinical residual disease who refused abdominoperi-
neal resection. Partial clinical response (pCR) was defined
as no evidence of residual tumor either in the rectal wall
(pT0) or in the regional lymph nodes (pN0) on pathologic
examination of the surgical specimen.
Study procedure
For the present study, the medical files of all eligible
patients were reviewed for demographics, medical history,
treatment details, imaging results at diagnosis and after
completion of preoperative CCRT, and pathologic stage
at surgery. Patients with incomplete data on preoperative
restaging by CT or EUS were excluded. In each case,
we compared the preoperative imaging findings with
the operative pathologic findings for T, N and TNM
stage. The performance of CT and EUS in predicting the
pathologic stage was assessed for each modality separately
(EUS vs. CT) and in combination (EUS +CT).
Statistical analysis
Quantitative data are expressed as mean value and cat-
egorical data as percentages. The preoperative T stage,
classified as T0 or T1-4, and N stage, classified as N0 or
N+, by imaging, was compared with the corresponding
postoperative T and N stage, as determined by patho-
logic study of the surgical specimen. Sensitivity, specifi-
city, and positive predictive value (PPV) were calculated
for each modality and for both together. For the T and
the TNM stages, which have more than two possible re-
sults, we calculated sensitivity, specificity, and PPV for
the relevant stage versus all others. SPSS software (ver-




A total of 292 patients with LARC underwent preoperative
CCRT at our medical center. Complete data on demo-
graphics, preoperative CT or EUS staging, and patho-
logical findings were available in 226 patients (77%),
who formed the study group. Their clinical and patho-
logic data at presentation are shown in Table 1. Mean
age of the patients was 64.5 years (range 28–88 years);
55% were male. None of the patients had a T1 tumor at
presentation; the majority (84%) had T3 tumors. Ninety-
one percent of the tumors were nonobstructing, well to
moderately differentiated adenocarcinomas.
Preoperative concurrent chemoradiation and surgery
Details of CCRT, surgical approach, and postoperative
chemotherapy, if applicable, are summarized in Table 2.
Table 1 Clinical characteristics at presentation in 226
patients with locally advanced rectal cancer







Distance from anal verge, n (%)
≤6 cm 112 (50)
>6 cm 114 (50)
Tumor size (cm)
Mean 5.21
Median (range) 5 (1–15)




Missing data 25 (12)
Endoscopic obstruction, n (%)
Yes 17 (8)
No 208 (92)
Histologic type, n (%)
Adenocarcinoma 221 (98)
Mucinous adenocarcinoma 5 (2)
Grade, n (%)
Well differentiated 49 (30)
Moderately differentiated 101 (61)
Poorly differentiated 14 (8)
Anaplastic 2 (1)





N stage, n (%)
N0 134 (65)
N+ 73 (35)
TNM stage, n (%)
0 0
I 22 (11)
Table 1 Clinical characteristics at presentation in 226




*Data were missing on luminal circumference (25 patients), endoscopic
obstruction (1 patient), grade (60 patients), T stage (19 patients), N stage
(19 patients), and TNM stage (19 patients).
Dickman et al. Radiation Oncology 2013, 8:278 Page 2 of 7
http://www.ro-journal.com/content/8/1/278Almost all patients (98%) received at least 45 Gy of ra-
diation, usually (98%) with continuous infusion of 5FU
or oral capecitabine. After a mean interval of 41 days
from completion of CCRT, patients underwent tumor
resection with curative intent: low anterior resection in
64%, abdominaoperineal resection in 36%, and local
excision in 0.4%.Table 2 Treatment data in 226 patients with locally
advanced rectal cancer
Value*







% receiving ≥45 Gy 98
Concurrent chemotherapy regimen, n (%)
Continuous infusion 5FU 91 (40)
Bolus 5FU 39 (17)
Capecitabine 90 (40)
Tegafur-uracil 6 (3)





Low anterior resection 143 (64)
Abdominoperineal resection 80 (36)
Local excision 1 (0.4)





*Data were missing on surgical treatment and adjuvant chemotherapy
(2 patients each).
CCRT, concurrent chemoradiation therapy.
Table 4 Positive predictive value (PPV), sensitivity, and
specificity of preoperative CT in identifying the pathologic
stage in patients with locally advanced rectal cancer
PPV Sensitivity Specificity
T stage
T0 36 (9/25) 60 (9/15) 80 (62/78)
T1 - - -
T2 25 (8/32) 33 (8/24) 65 (45/69)
T3 72 (23/32) 47 (23/49) 80 (35/44)
T4 - - -
N stage 27 (3/11) 4 (3/74) 50(8/16)
TNM stage
0 35 (9/26) 60 (9/15) 79 (63/80)
I 34 (11/32) 39 (11/28) 69 (46/67)
II 50 (11/22) 30 (11/37) 81 (47/58)
III 46 (6/13) 50 (6/12) 92 (76/83)
IV - - -
Note: Data are expressed in percentage (number of patients out of
relevant total).
Sensitivity and specificity of each T and TNM stage were calculated as the
relevant T stage versus all others.
(−) refers to groups with fewer than 5 patients.
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EUS was used for preoperative restaging in 138 patients
(61%), CT in 94 (42%), PET in 18 (8%), and MRI in 3
(1%). Data on preoperative restaging in patients who
underwent both CT and EUS were available in 80
patients (35%); data on pathological N stage were available
for all patients but one. The combination of EUS and
CT yielded T0 disease in 5% of patients and T1-4 disease
in 95%, and clinical N + disease in 15% of patients and
N0 disease in 85%. Pathologic examination of the surgical
specimens revealed that 5% of the patients had pT0
disease and 85%, pT1-T4; 11% had pN1-2 disease, and
89%, N0 disease.
Predictive value of preoperative CT
Data on the preoperative CT findings for T stage were
available in 93 patients, for N stage, in 90 patients, and
for overall clinical TNM stage, in 95 patients. Table 3
summarizes the pathologic stage for each CT-predicted
stage, and Table 4 summarizes the PPV, sensitivity, and
specificity of preoperative CT in predicting each patho-
logic T, N, and TNM stage. The overall PPV for pT stage
was 44%. However, in the subgroup of patients with
CT-predicted T3 disease, the PPV was particularly
high (72%). The overall PPV for TNM stage was 31%.
The highest concordance was observed in patients with
preoperative clinical stage II (50%) and III (46%). CTTable 3 Preoperative CT-based clinical stage and
corresponding postoperative pathologic stage in patients
with locally advanced rectal cancer
CT T stage n = 93 Pathologic T stage n = 93
T stage n (%) T0 T1 T2 T3 T4
T0 25 (27) 9 (36) 1 (4) 9 (36) 6 (24) 0
T1 3 (3) 1 (33) - - 2 (66) 0
T2 32 (34) 3 (9) 4 (12.5) 8 (25) 17 (53) 0
T3 32 (34) 2 (6) 0 7 (22) 23 (72) 0
T4 1 (1) - - - 1 (100) 0
CT N stage n = 90 Pathologic N stage n = 90
N stage n (%) pN0 pN+
N0 79 (88) 71 (90) 8 (10)
N+ 11 (12) 8 (73) 3 (27)
CT TNM stage n = 95 Pathologic TNM stage n = 95
TNM stage n (%) 0 I II III IV
0 26 (27) 9 (35) 10 6 (23) 1 (4) -
I 32 (34) 4 (12.5) (38.5) 14 (44) 2 (6) 1 (3)
II 22 (23) 2 (9) 11 (34) 11 (50) 3 (14) -
III 13 (14) - 6 (27) 6 (46) 6 (46) -
IV 2 (2) - 1 (8) - - 2 (100)
Note: Data are expressed as n (%).
(−) refers to groups with no patients.
CT, computerized tomography.accurately predicted N0 disease in 71 of 88 patients (90%)
with pathologic N0 disease, and accurately predicted
N + disease in 3 of 11 patients (27%) with pathologic
pN1 disease.
Predictive value of preoperative EUS
Data on the preoperative EUS findings for T stage were
available in 139 patients, for N stage in 138 patients, and
for overall clinical TNM stage, in 140 patients. Table 5
summarizes the pathologic stage for each EUS-predicted
stage, and Table 6 summarizes the PPV, sensitivity, and
specificity of preoperative EUS in predicting each patho-
logic T, N, and TNM stage. The overall PPV for pT stage
was 49%, and for TNM stage, 42%. EUS accurately pre-
dicted pN0 disease in 105 of 120 patients (87.5%) with
pathologic pN0 disease, and accurately predicted N + dis-
ease in 4 of 18 patients (22%) with pathologic N + disease.
Predictive value of combined preoperative CT and EUS
Table 7 summarizes the pathologic stage for each CT-
and EUS-predicted tumor stage in the 80 patients for
whom data for both modalities were available, and
Table 8 summarizes the PPV, sensitivity, and specificity
of preoperative CT plus EUS in predicting each patho-
logic T, N, and TNM stage. Overall, the PPV of CT plus
EUS in predicting the pT stage was 55%. Among patients
with pathologic stage T3 disease, 58% were correctly
identified by CT plus EUS. The corresponding rate for
pathological TNM stage was 52%. Of the 68 patients
with stage pN0 disease, 60 (88%) were correctly identified
Table 5 Preoperative EUS-based clinical staging and the corresponding postoperative pathologic stage
EUS T stage n = 139 Pathologic T stage n = 139
T stage n (%) T0 T1 T2 T3 T4
T0 19 (14) 7 (37) 3 (16) 2 (10.5) 7 (37) -
T1 10 (7) 1 (10) 4 (40) 4 (40) 1 (10) -
T2 30 (22) 3 (10) 2 (7) 11 (37) 14 (47) -
T3 77 (55) 10 (13) 3 (4) 24 (31) 40 (52) -
T4 3 (2) - - - 3 (100) -
EUS N stage n = 138 Pathologic N stage n = 138
N stage n (%) pN0 pN+
N0 120 (87) 105 (87.5) 15 (12.5)
N+ 18 (13) 14 (78) 4 (22)
EUS TNM clinical stage n = 140 Pathologic TNM stage n = 140
TNM stage n (%) 0 I II III IV
0 25 (18) 7 (28) 9 (36) 7 (28) 1 (4) 1 (4)
I 34 (24) 3 (9) 16 (47) 9 (26.5) 5 (15) 1 (3)
II 63 (45) 7 (11) 21 (33) 25 (40) 10 (16) -
III 18 (13) 3 (17) 4 (22) 6 (33) 4 (22) 1 (6)
IV 0 - - - - -
Note: Data are expressed as n (%).
(−) refers to groups with no patients.
EUS, endorectal ultrasonography.
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disease, 2 (17%) were correctly identified.
Discussion
Valid preoperative restaging after chemoradiation for
LARC is crucial to determine the individualized treatmentTable 6 Positive predictive value (PPV), sensitivity, and
specificity of preoperative EUS in identifying the pathologic
stage in patients with locally advanced rectal cancer
PPV Sensitivity Specificity
T stage
T0 37 (7/19) 33 (7/21) 90 (106/118)
T1 - - 95 (117/123)
T2 37 (11/30) 27 (11/41) 80 (79/98)
T3 52 (40/77) 61 (40/65) 50 (37/74)
T4 - - -
N stage 22 (4/18) 4 (4/109) 52 (15/29)
TNM stage
0 28 (7/25) 35 (7/20) 85 (102/120)
I 47 (16/34) 32 (16/50) 80 (72/90)
II 40 (25/63) 53 (25/47) 59 (55/93)
III - - 88 (106/120)
IV - - -
Data are expressed in percentage (number of patients out of relevant total).
Sensitivity and specificity of each T and TNM stage were calculated as the
relevant T stage versus all others.
(−) refers to groups with less than 5 patients.strategy. However, despite improvements in different
imaging modalities, their performance and role in staging
rectal cancer remain controversial [16]. Assessment of
rectal wall involvement by the tumor on the basis of
EUS or CT scans often leads to underestimation of the
pathologic response. At the same time, over staging by
CT or EUS occurs in approximately 18% of cases, and
up to 23% of patients considered to have N0 disease at
initial staging have pathologic nodal metastases at surgery
[14,17]. Staging failures with phased array MRI have also
been reported, mainly in the differentiation of T2 from
borderline T3 tumors [11,17]. Furthermore, rectal wall
infiltration does not always correlate with tumoral
lymph node involvement, even in patients with pCR in
the rectal wall [18].
Given the apparently poor association between pre-
operative restaging by a single imaging modality and the
pathologic findings, we speculated that combining two
imaging modalities might improve the prediction of
tumor stage before surgery. This retrospective study
sought to assess the performance of two commonly
used imaging modalities, EUS and CT, in this setting.
Our results indicate that the performance of combined
EUS plus CT is equally poor to the performance of
each modality alone. The only fair PPV achieved was
for T3 stage; the PPV for all other T stages was low.
Denecke et al. [6], using a similar study design to ours,
investigated the performance of CT, PET, and MRI in
23 patients with stage T3-T4 LARC. In accordance with
Table 7 Preoperative combined EUS plus CT- based clinical stage and corresponding postoperative pathologic stage in
patients with locally advanced rectal cancer
CT plus EUS T stage n = 80 Pathologic T stage n = 80
T stage n (%) T0 T1 T2 T3 T4
T0 4 (5) 4 (100) - - - -
T1 5 (6) - 1 (20) 3 (60) 1 (20) -
T2 17 (21) 1 (6) 2 (12) 5 (29) 9 (53) -
T3 52 (66) 7 (13) 2 (4) 13 (25) 30 (58) -
T4 2 (2) - - - 2 (100) -
CT plus EUS N stage n = 80 Pathologic N stage n = 79
N stage n (%) pN0 pN+
N0 68 (85) 60 (88) 7 (10)
N+ 12 (15) 10 (83) 2 (17)
CT plus EUS clinical stage n = 80 Pathologic TNM stage n = 80
TNM stage n (%) 0 I II III IV
0 4 (5) 4 (100) - - - -
I 18 (22) 1 (6) 9 (50) 6 (33) 1 (6) 1 (6)
II 44 (55) 6 (14) 13 (30) 20 (45) 5 (11) -
III 13 (16) 1 (8) 2 (15) 6 (46) 4 (31) -
IV 1 (1) - - - - 1 (100)
Data are expressed in number (%).
(−) refers to groups with no patients.
CT, computerized tomography, EUS, endorectal ultrasonography.
Table 8 Positive predictive value (PPV), sensitivity and
specificity of preoperative CT plus EUS in identifying the
pathologic stage in patients with locally advanced rectal
cancer
Combined CT plus EUS
PPV Sensitivity Specificity
T stage
T0 - - 100 (68/68)
T1 - - 95 (71/75)
T2 29 (5/17) 24 (5/21) 80 (47/59)
T3 58 (30/52) 56 (30/54) 15 (4/26)
T4 - 97 (66/68)
N stage 17 (2/12) 3 (2/60) 41 (7/17)
TNM stage
0 - - 100 (68/68)
I 50 (9/18) 37 (9/24) 84 (47/56)
II 45 (20/44) 67 (20/32) 50 (24/48)
III - - 87 (61/70)
IV - - 100 (78/78)
Data are expressed in percentage (number of patients out of relevant total).
Sensitivity and specificity of each T and TNM stage were calculated as the
relevant T stage versus all others.
(−) refers to groups with less than 5 patients.
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only. However, Denecke et al. [6] did not assess T1-T2
tumors, so a full comparison between the studies cannot
be made. Moreover, in line with our findings, other studies
reported a low yield for morphological imaging modalities
in predicting the pathologic response of various stages of
LARC [9,19]. Beets-Tan et al. [19,20] noted that CT and
MRI had only 50% accuracy in identifying the depth of
tumor infiltration after therapy.
One explanation for these findings may be therapy-
induced changes in the tissue surrounding the tumor. It
has been suggested that external beam radiation produces
a strong desmoplastic reaction and fibrosis which impede
the detection of tumor regression by morphological
imaging modalities [19]. Additionally, radiation may
induce changes in the rectal wall and lymph nodes
that render the assessment of preoperative treatment
and restaging more difficult [6].
Although EUS has been found very accurate for staging
of superficial T1 and T2 rectal tumors, it performs less
well in the initial staging of rectal cancer and in restaging
LARC after CCRT. In our study, the overall PPV of pre-
operative EUS was poor, even after it was combined with
preoperative CT. Similar observations were made by other
studies suggesting that the accuracy of EUS decreases with
an increase in the depth of tumor infiltration [8,9], mainly
because of the limited depth of acoustic penetration,
particularly in bulky T3 tumors and advanced rectal
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are the operator dependency of EUS and its limited ability
to differentiate among tumor, scar tissue, and normal
tissue after preoperative CCRT.
By contrast to other reports, we found that CT and EUS,
alone or in combination, exhibited good performance
in predicting pN0 stage disease. This discrepancy may
be related to the relatively large cohort in the present
study. If validated, our finding may have important
implications in certain clinical settings. For example, it
may support the use of local excision instead of abdo-
minoperineal resection in patients with distal disease
in whom CCRT leads to complete disappearance of
the tumor in the rectal wall and neither CT nor EUS
reveals suspect lymph nodes [21].
The limitations of our study are its retrospective design,
which may have affected the completeness of the data,
and its long duration, which may have contributed to
the heterogeneity of imaging and therapeutic techniques
used during different time periods. Moreover, the incon-
sistent timing of the performance of the different imaging
modalities and of surgery may have affected the accuracy
of the preoperative staging. There is also evidence that
the interval from the completion of preoperative CCRT
to surgery may affect the pathologic stage [22]. Finally,
the predictive value of preoperative CT and EUS may
have been affected by the large number of patients
treated by neoadjuvant CCRT at our center who were
not restaged. This was a retrospective study and as such,
there was no patient selection for restaging. Missing
preoperative CT findings was significant, and it was the
only criterion for excluding patients in the analysis.
Another limitation of our study is the lack alternative
procedures or imaging modalities such as MRI or
FDG-PET. In fact, one of the promising directions for
improving current imaging methods for restaging LARC
following preoperative CCRT is combining morphological
and metabolic changes using FDG-PET. Indeed, several
studies have shown that FDG-PET has remarkable diag-
nostic accuracy for both rectal masses and metastatic
sites [15,23]. In addition, there is some evidence that
early FDG-PET, done during the course of CCRT, may
be even more accurate in predicting pCR than PET-CT
done after the completion of treatment [24,25]. In a recent
systematic review and meta-analysis, the performance
values of MRI for restaging locally advanced rectal cancer
after neoadjuvant treatment were assessed. MRI imaging
showed heterogeneous results of diagnostic performances
for restaging rectal cancer after neoadjuvant treatment
[26]. However, significantly better results were demon-
strated when diffusion-weighted (DW) imaging was used
or with experienced observers. MRI can also be used for
evaluation of circumferential resection margins staging,
but nodal staging remains challenging [26]. Another studythat assessed the efficacy of high-resolution magnetic
resonance imaging (HRMRI) for preoperative local staging
in patients with rectal cancer found that HRMRI provides
good predictive data for extramural invasion but poor
prediction of lymph node status and circumferential
resection margins involvement [27].
Conclusions
In patients after CCRT for LARC, neither EUS nor CT
seems to be sufficiently accurate to serve as a basis for
decisions on treatment modifications, although both
show potential for excluding nodal involvement. The
accuracy of the combined use of these modalities does
not exceed that of each modality alone.
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